InvestSMART

Neuren Pharmaceuticals Limited (ASX:NEU)

ALERT: Price-sensitive ASX Announcement for NEU
Current share price for NEU : $20.670 -1.86 (-8.26%)+
Announcement
Release
26 Aug 2026 9:25AM
Price at Release
$22.530
Full Release
download
Summary
For the half-year ending June 30, 2026, Neuren Pharmaceuticals Limited reported a profit of A$4.9 million, a significant decrease from A$15 million in the previous year. The decline in profit was attributed to increased research and development costs, which rose to A$27.4 million, largely due to the Phase 3 clinical trial of NNZ-2591 in Phelan-McDermid syndrome (PMS). Revenue from royalties, primarily from Acadia Pharmaceuticals for DAYBUE (trofinetide), increased to A$33.2 million. This revenue growth was complemented by finance income of A$5.6 million and foreign currency gains of A$4 million. Neuren also announced its first interim dividend policy, paying a fully franked dividend of 15.0 cents per share. The company's consolidated interim financial statements demonstrate stable asset and liability figures compared to December 2025, with total assets slightly decreasing to A$340.6 million. The report reflects Neuren's ongoing strategic focus on advancing clinical trials and strengthening financial performance despite variable operating expenses.
Key Points
  • Profit after tax for H1 2026 was A$4.9 million, down from A$15 million in H1 2025.
  • Research and development expenses increased to A$27.4 million due to the Phase 3 trial.
  • Revenue from royalties increased to A$33.2 million.
  • An interim dividend of 15.0 cents per share was declared.
  • Total assets were reported at A$340.6 million.
  • Neuren's financial results were influenced by increased investment in research and development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.